Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

81. Magnesium added to bupivacaine prolongs the duration of analgesia after interscalene nerve block (PubMed)

Magnesium added to bupivacaine prolongs the duration of analgesia after interscalene nerve block Local anesthetic adjuvants have been studied previously in an attempt to prolong the duration of analgesia after peripheral nerve blockade. Magnesium has been shown to have an antinociceptive effect in animal and human pain models. We evaluated the effects of adding magnesium sulphate to long-acting local anesthetics for interscalene nerve block to prolong the duration of analgesia and improve (...) the analgesic quality.We enrolled 66 patients undergoing arthroscopic rotator cuff repair. The interscalene nerve block was performed with 0.5% bupivacaine 20 mL with epinephrine (1:200,000) plus either 10% magnesium sulphate 2 mL (Magnesium Group) or normal saline 2 mL (Saline Group). The following data were recorded for 24 hr after surgery: onset times and durations of sensory and motor blocks, analgesic duration, the pain numeric rating scale (NRS), postoperative fentanyl consumption

Full Text available with Trip Pro

2012 EvidenceUpdates

82. Magnesium Laboratory Testing for Patients admitted for Heart Failure: Clinical Effectiveness and Guidelines

Magnesium Laboratory Testing for Patients admitted for Heart Failure: Clinical Effectiveness and Guidelines Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time (...) for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Magnesium Laboratory

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

83. Magnesium for Pre-Eclampia

Magnesium for Pre-Eclampia Magnesium for Pre-Eclampia – TheNNTTheNNT Magnesium Sulfate for Women with Preeclampsia 90 for seizure In Summary, for those who received the magneisum: Benefits in NNT For the mother: 98.8% saw no benefit 1.2% were helped by preventing a seizure For the child: 100% saw no benefit 0% were helped by avoiding mortality, NICU stay, preterm delivery For the mother: 1 in 90 were helped (seizure prevented) For the child: None were helped (death, NICU stay, avoiding preterm (...) maternal death). Although the mechanism is unclear magneisum sulfate has been used to prevent eclampsia since the 1950s. In this cochrane review, 11,444 women in 15 randomized trials were recruited from a mix of high, middle, and low income countries. The largest is the 33-country MagPie Trial comparing intravenous magnesium to placebo. The study was published in 2002 and at >10,000 subjects accounts for more than 87% of those in the review. The use of magnesium sulfate was associated with a greater

2012 theNNT

84. Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth. (PubMed)

Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth. The effectiveness of antenatal magnesium sulphate for neuroprotection of the fetus, infant, and child prior to very preterm birth, when given to women considered at risk of preterm birth, has been established. There is currently no consensus as to the regimen to use in terms of the dose, duration, the use of repeat dosing and timing.To assess the comparative effectiveness and adverse (...) effects of different magnesium sulphate regimens for neuroprotection of the fetus in women considered at risk of preterm birth.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 December 2011).Randomised trials comparing different magnesium sulphate regimens when used for neuroprotection of the fetus in women considered at risk of preterm birth. We planned to include cluster trials. We planned to exclude quasi-randomised trials and those with a crossover design. We planned

2012 Cochrane

85. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. (PubMed)

Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Magnesium sulphate is a neuroprotective agent that might improve outcome after aneurysmal subarachnoid haemorrhage by reducing the occurrence or improving the outcome of delayed cerebral ischaemia. We did a trial to test whether magnesium therapy improves outcome after aneurysmal subarachnoid haemorrhage.We did this phase 3 randomised, placebo-controlled trial in eight centres in Europe and South (...) America. We randomly assigned (with computer-generated random numbers, with permuted blocks of four, stratified by centre) patients aged 18 years or older with an aneurysmal pattern of subarachnoid haemorrhage on brain imaging who were admitted to hospital within 4 days of haemorrhage, to receive intravenous magnesium sulphate, 64 mmol/day, or placebo. We excluded patients with renal failure or bodyweight lower than 50 kg. Patients, treating physicians, and investigators assessing outcomes

Full Text available with Trip Pro

2012 Lancet

86. Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy (PubMed)

Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy In a randomized, double-blind, prospective study, we investigated whether an intraoperative high versus low dose of remifentanil increased postoperative hyperalgesia and whether magnesium can prevent remifentanil-induced hyperalgesia.Ninety patients undergoing thyroidectomy were randomly assigned to 1 of 3 groups. Remifentanil was intraoperatively infused at 0.05 μg/kg/min (group LO

Full Text available with Trip Pro

2011 EvidenceUpdates

87. Magnesium-Essentials for Anesthesiologists (PubMed)

Magnesium-Essentials for Anesthesiologists Magnesium plays a fundamental role in many cellular functions, and thus there is increasing interest in its role in clinical medicine. Although numerous experimental studies indicate positive effects of magnesium in a variety of disease states, large clinical trials often give conflicting results. However, there is clear evidence for magnesium to benefit patients with eclampsia or torsades de pointes arrhythmias. In addition, magnesium seems to have (...) antinociceptive and anesthetic as well as neuroprotective effects, yet well-designed large clinical trials are required to determine its actual efficacy in pain management or in the state of stroke or subarachnoid hemorrhage. The current review aims to provide an overview of current knowledge and available evidence with respect to physiologic aspects of magnesium and proposed indications and recommendations for its use in the clinical setting.

Full Text available with Trip Pro

2011 EvidenceUpdates

88. Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage

Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage BestBets: Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage Report By: Daniel Horner - ST4 Emergency Medicine / Critical Care Search checked by Craig Ferguson - SpR Emergency Medicine Institution: Manchester Royal Infirmary Date Submitted: 1st May (...) 2010 Date Completed: 27th January 2011 Last Modified: 27th January 2011 Status: Green (complete) Three Part Question In a patient presenting with [aneurysmal subarachnoid haemorrhage] does [early elevation of serum magnesium by administration of intravenous magnesium sulphate] lead to a reduction in [subsequent vasospasm incidence, morbidity or mortality rates] Clinical Scenario A 40 year old female attends the emergency department as a standby call. Her partner gives you a history of acute

2011 BestBETS

89. Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 (PubMed)

Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 Cumulative sensory neurotoxicity (sNT) is the dose-limiting toxicity of oxaliplatin, which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant settings. In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT.Patients with colon cancer undergoing (...) adjuvant therapy with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were randomly assigned to Ca/Mg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo, in a double-blinded manner. The primary end point was the percentage of patients with grade 2 or greater sNT at any time during or after oxaliplatin-based therapy by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; version 3) criteria. An oxaliplatin-specific sNT

Full Text available with Trip Pro

2011 EvidenceUpdates

90. The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial (PubMed)

The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial To determine whether nightly administration of melatonin, magnesium, and zinc improves primary insomnia in long-term care facility residents.Double-blind, placebo-controlled clinical trial.One long-term care facility in Pavia, Italy.Forty-three participants with primary insomnia (22 in the supplemented group, 21 in the placebo group (...) ) aged 78.3 ± 3.9.Participants took a food supplement (5 mg melatonin, 225 mg magnesium, and 11.25 mg zinc, mixed with 100 g of pear pulp) or placebo (100 g pear pulp) every day for 8 weeks, 1 hour before bedtime.The primary goal was to evaluate sleep quality using the Pittsburgh Sleep Quality Index. The Epworth Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire (LSEQ), the Short Insomnia Questionnaire (SDQ), and a validated quality-of-life instrument (Medical Outcomes Study 36-item Short

2011 EvidenceUpdates

91. Magnesium Sulphate for Fetal Neuroprotection

Magnesium Sulphate for Fetal Neuroprotection Magnesium Sulphate for Fetal Neuroprotection - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 33, Issue 5, Pages 516–529 Magnesium Sulphate for Fetal Neuroprotection PRINCIPAL AUTHORS, x Laura Magee , MD Vancouver BC x Diane Sawchuck , RN, PhD Vancouver BC x Anne Synnes , MD Vancouver BC x Peter von Dadelszen , MBChB Vancouver BC x THE MAGNESIUM SULPHATE FOR FETAL (...) as a subscribed user or . Click to view the full text on ScienceDirect. Abstract Objective To provide guidelines for the use of antenatal magnesium sulphate (MgSO 4 ) for fetal neuroprotection of the preterm infant. Options Antenatal MgSO4 administration should be considered for fetal neuroprotection when women present at ≤ 31+6 weeks with imminent preterm birth, defined as a high likelihood of birth because of active labour with cervical dilatation ≥ 4 cm, with or without preterm pre-labour rupture

Full Text available with Trip Pro

2011 Society of Obstetricians and Gynaecologists of Canada

92. Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth

Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Scientific Impact Paper No. 29 August 2011Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth 1. Background The prevalence of preterm birth is increasing. 1 While the survival of infants born preterm has improved, 2 the prevalence of cerebral palsy has risen. 3 The incidence of cerebral palsy decreases significantly with increasing (...) to reduce the effects of this disabling condition on individuals, families, health care and society. 2. Neuroprotection In the late 1990s studies of infants born to mothers given magnesium sulphate to prevent eclamptic seizures or as tocolysis showed a reduction in rates of cystic periventricular leucomalacia (PVL) and cerebral palsy. In those babies born preterm and exposed to magnesium sulphate 8 the odds ratio for cerebralpalsywas0.14(95%CI0.05–0.51). 9 Althoughtheexactmechanismofactionofmagnesium

2011 Royal College of Obstetricians and Gynaecologists

93. Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis

Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Cahill AG, Odibo AO, Stout MJ, Grobman WA, Macones GA, Caughey AB Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of magnesium treatment, for pregnant women at high risk of delivery before 32 weeks gestation, for the prevention of cerebral palsy in pre-term infants. Based on the evidence available, magnesium

2011 NHS Economic Evaluation Database.

94. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study

Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2010 PedsCCM Evidence-Based Journal Club

95. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. (PubMed)

Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Magnesium sulphate remains the drug of choice for both prevention and treatment of women with eclampsia. Regimens for administration of this drug have evolved over the years, but have not yet been formally evaluated.To assess the comparative effects of alternative regimens for the administration of magnesium sulphate when used for the care of women with pre-eclampsia or eclampsia, or both.We searched (...) the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2010).Randomised trials comparing different regimens for administration of magnesium sulphate used for the care of women with pre-eclampsia or eclampsia, or both.All four review authors assessed trial quality and extracted data independently.We identified 17 studies of which six (866 women) met the inclusion criteria: two trials (451 women) compared regimens for women with eclampsia and four (415 women) for women with pre

2010 Cochrane

96. Efficacy and Tolerability of Split-Dose Magnesium Citrate: Low-Volume (2 Liters) Polyethylene Glycol vs. Single- or Split-Dose Polyethylene Glycol Bowel Preparation for Morning Colonoscopy (PubMed)

Efficacy and Tolerability of Split-Dose Magnesium Citrate: Low-Volume (2 Liters) Polyethylene Glycol vs. Single- or Split-Dose Polyethylene Glycol Bowel Preparation for Morning Colonoscopy Preparation regimens for morning colonoscopy are suboptimal. The aim of this study was to test the efficacy and tolerance of a split-dose magnesium citrate-low-volume (2 liters) polyethylene glycol (PEG) regimen for morning colonoscopy.A total of 232 patients were randomly assigned to receive 4 liters PEG (...) (day before procedure; group 1, n=79), 2 liters PEG (day before procedure) followed by another 2 liters PEG (day of procedure; group 2, n=80), or magnesium citrate (250 ml, day before procedure) followed by 2 liters PEG (day of procedure; group 3, n=73). The quality of bowel cleansing, tolerability, and adverse effects in group 3 were compared with those in groups 1 and 2.Satisfactory bowel preparation was more frequently reported for group 3 than for group 1 (75% vs. 51%, P=0.001) and was similar

2010 EvidenceUpdates

97. Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: A randomized controlled study

Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: A randomized controlled study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2010 PedsCCM Evidence-Based Journal Club

98. SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution

SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution Drug Approval Package: SUPREP (sodium sulfate, potassium sulfate, magnesium sulfate) NDA #022372 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution Company: Braintree Laboratories, Inc. Application No.: 022372 Approval Date: 08/05/2010 Persons with disabilities having problems

2010 FDA - Drug Approval Package

99. Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets

Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Company: Pozen Application No.: 022511 Approval Date: 4/30/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2010 FDA - Drug Approval Package

100. Magnesium Sulfate for Asthma Attack

Magnesium Sulfate for Asthma Attack Magnesium Sulfate for Asthma Attack – TheNNTTheNNT Intravenous Magnesium Sulfate Given During an Asthma Attack 3 for prevented hospital admission In Summary, for those who took the magnesium: Benefits in NNT 67% saw no benefit 33.3% of severe asthmatics were helped by preventing hospital admission 1 in 3 were helped (preventing hospital admission if patient is a "severe asthmatic") None were helped (preventing hospital admission if patient is not a "severe (...) asthmatic") Harms in NNT 0% of severe asthmatics were harmed by serious side effects 100% of non-severe asthmatics were neither helped nor harmed None were harmed (serious side effects, vital sign abnormalities) View As: NNT % Source: Efficacy Endpoints: Hospital admission Harm Endpoints: Tachycardia, tremor Narrative: This review included 7 trials, (N = 665) of which 5 were adult and 2 pediatric. Magnesium sulfate was administered early in the study period, in the first 60 minutes in 5 of the studies

2010 theNNT